Basic Information
| LncRNA/CircRNA Name | NORAD |
| Synonyms | NA |
| Region | GRCh38_20:36045622-36050960 |
| Ensemble | ENSG00000260032 |
| Refseq | NR_027451 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Neuroblastoma |
| ICD-0-3 | NA |
| Methods | qPCR, RNA-seq |
| Sample | cell lines(SK-N-BE, SMS-KAN, SMS-KCN, CHLA-15, CHLA-122, NBL-W, SMS-KANR, SMS-KCNR, CHLA-20, CHLA-136, NBL-WR) |
| Expression Pattern | up-regulated |
| Function Description | Of the 17 lncRNAs, 3 upregulated (NEAT1, SH3BP5-AS1, NORAD) and 3 downregulated lncRNAs (DUBR, MEG3, DHRS4-AS3) were also found to be differentially expressed in favorable compared with unfavorable outcome. |
| Pubmed ID | 30886518 |
| Year | 2019 |
| Title | Clinically Relevant Biomarker Discovery in High-Risk Recurrent Neuroblastoma. |
External Links
| Links for NORAD | GenBank HGNC NONCODE |
| Links for Neuroblastoma | OMIM COSMIC |